New guidelines on anaemia management in patients with cancer: How do these affect clinical practice?

Oncology

Volumn 69, Issue SUPPL. 2, 2005, Pages 17-21

  Birgegård, Gunnar ^a,d   Bokemeyer, Carsten ^b,c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Department of Haematology and Oncology ^*  (Germany)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anaemia management; Epoetin beta; Guidelines

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER; CLINICAL PRACTICE; DRUG EFFICACY; HUMAN; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION;

EID: 27144508790     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088284     Document Type: Article

References (32)

1. Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK: Patient, care-giver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34(suppl 2):4-12.
2. Dillon E, Kelly J, AIFC: The status of cancer fatigue on the island of Ireland: AIFC professional and interim patient surveys. Oncologist 2003;8:22-26.
3. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D: Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95:155-163.
4. Block KI: Pain, depression, and fatigue in cancer. Integr Cancer Ther 2002;1:323-326.
5. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Dimeo F, Fetscher S, Lange W, Mertelsmann R, Keul J: Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood 1997;90:3390-3394.
7. Oldervoll LM, Kaasa S, Knobel H, Loge JH: Exercise reduces fatigue in chronic fatigued Hodgkins disease survivors - results from a pilot study. Eur J Cancer 2003;39:57-63.
8. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS; American Society of Clinical Oncology: American Society of Hematology. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
9. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Österborg A, Repetto L, Soubeyran P: EORTC guidelines forthe use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-2216.
10. National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology - v. 1.2004. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/anemia.pdf.
11. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
12. Demetri GD, Kris M, Wade J, Degos L, Cella D: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
13. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJ, Reed NS, Fairlamb DJ, Chan SY, Godfrey KA, Kristensen GB, van Tinteren H, Ehmer B: Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15:174-182.
14. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D; Epoetin Beta Hematology Study Group: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494.
15. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
16. Boogaerts M, Coiffier B, Kainz C, Epoetin beta QOL Working Group: Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 2003;88:988-995.
17. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B: Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-393.
18. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ, Darbepoetin Alfa 20000161 Study Group: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
19. Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercammen E, Schuette W, Wils J, Freund M, Epoetin Alfa Study Group: Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 2003;21:169-180.
20. Shasha D, George MJ, Harrison LB: Once-weekly dosing of epoetin-alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.
21. Leonard RC, Aapro M, Chan S, Dirix LY, Mayordomo J, Reichert D, Untch M: Once weekly epoetin beta in patients with metastatic breast cancer receiving anthracycline- or taxane-based chemotherapy. Ann Oncol 2004;15(suppl 3):Abstract 188P.
22. Chang J, Couture F, Young S, McWatters KL, Lau CY: Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. Clin Oncol 2005;23:2597-2605.
23. Heras P, Argyriou AA, Papapetropoulos S, Karagiannis S, Argyriou K, Mitsibounas D: The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients. Eur J Cancer Care 2005;14:108-112.
24. Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, Glaspy J: Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer 2002;3:180-190.
25. Leyland-Jones B, BEST Investigators and Study Group: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
26. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
27. Aapro M, Dunst J, Morère JF, Nowrousian MR, Huber M, Burger HU: Effect of epoetin beta on tumour progression and survival in patients with cancer: a meta-analysis of controlled clinical studies. Ann Oncol 2004;15(suppl 3):abstract 841P.
28. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, Engert A: Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 2003, vol 3:CD003407.
29. Coiffier B, Boogaerts M, Aapro M, Huber M, Burger HU: Thromboembolic events in patients with cancer treated with epoetin beta: A meta-analysis of controlled clinical trials. Ann Oncol 2004;15(suppl 3):abstract 840P.
30. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
31. Van Belle S, Paridaens R, Evers G, Kerger J, Bron D, Foubert J, Ponnet G, Vander Steichel D, Heremans C, Rosillon D: Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool. Support Care Cancer 2004;13:246-2154.
32. Nelson EC, Wasson JH, Johnson D, Hays R: Dartmouth COOP functional health assessment charts: Brief measures for clinical practice; in Spilkar B (eds): Quality of life and Pharmacoeconomics in Clinical Trials, ed 2. Philadelphia, Lippincott-Raven Publishers, 1996.